Ranbaxy Pharmaceuticals Inc. of India is recalling lots of their generic version of the cholesterol drug Lipitor because they may contain glass particles. The recall is the latest incident in a string of quality control lapses that has led the U.S. Food and Drug Administration to increase scrutiny of the company.
Tablets of atorvastatin calcium, the generic version of the best-selling cholesterol-fighting drug Lipitor, in 10-, 20-, and 40-milligram doses are affected by the recall. The 80-milligram dose is not a part of the recall. For a complete list of the recalled products, click here.
An investigation into manufacturing defects and lax testing procedures led the FDA to ban the importation of drugs from Ranbaxy in 2008. The U.S. Justice Department also investigated the company for making misleading claims about ingredients and formulas for some medications. The company was only allowed to begin selling drugs in the U.S. after signing a consent decree with the FDA whereby Rabaxy agreed to improve their operations and be reviewed by an independent third party for the next five years.
If you have experienced a serious injury due to packaging error, a defective products attorney may be able to help you pursue the compensation you deserve. For more information, call 1-888-BURNETTI.